Oxford - 6 May
Join us for an engaging lunchtime networking event in Oxford, delivered in collaboration with OBN.
Are you getting real value from your CRO or just ticking a box?
In early-stage biotech, every decision counts. The way you design your development programme and how you use your CRO can accelerate your path to clinic or quietly drain time, budget, and investor confidence.
Too many start-ups bring in CROs too late, use them too tactically or fail to connect their data strategy to funding and regulatory milestones.
This event is built for biotech start-ups and early-stage teams to change that. Are you….
• Preparing for your next funding round
• Building your proof of concept
• Scaling from discovery into development
• Working with (or about to engage) a CRO
This session will give you practical, immediately usable insight to de-risk your programme and strengthen your investor story.
You’ll learn
• How to avoid the hidden causes of delays and costly remediation
• Why “designing it right first time” is critical to preserving runway and valuation
• How to treat data as a strategic asset, not just an output
• When to engage your CRO to maximise impact, not just execution
Hear directly from a venture capital expert on how your programme is assessed behind closed doors. Insights into what investor ready proof of concept actually looks like, why CMC, analytical strategy and data quality are being scrutinised earlier than ever and where and why deals most often fall apart
Speakers
Jette Cowen – Head of Commercial, RSSL
Julian Rae – Senior Associate Principal Scientist, RSSL
Daniel Nicolau – Associate Principal Scientist, RSSL
Yasir Hassan – Venture Capital (VC) Expert
Following our workshop, you will gain a clearer strategy to use CROs as a competitive advantage, insight into how investors really evaluate your programme and practical ways to reduce risk, save time and protect capital
This complimentary event is available on an apply to attend basis.
Learn more and register your interest to attend today.
